Latest news with #AditiPanandikar
Time of India
3 days ago
- Business
- Time of India
Initiative appointed as Media Agency on Record for Sensodent
Initiative has been appointed as the media agency on record for Sensodent , a specialised oral care brand from Indoco Remedies , a Mumbai-based pharmaceutical company. As Sensodent gears up to strengthen its leadership in the oral sensitivity segment, Initiative will lead the brand's media strategy, planning, and deployment across platforms—focusing on driving awareness, trials, and brand relevance at scale. The media mandate was awarded following a multi-agency pitch process . Commenting on this development, Aditi Panandikar, managing director, Indoco Remedies said, 'Our brand Sensodent is the first to go OTC and over the year has evolved into the next orbit. We are thrilled to work together with Initiative and are looking forward to see our brand soaring newer heights.' Dhirendra Singh, executive vice president and head – Mumbai, Initiative, said, "Sensodent K is a high-potential brand in a growing yet underpenetrated category. We're excited to partner with Indoco Remedies to architect a media approach that drives performance, builds cultural relevance, and connects meaningfully with consumers across India." Speaking on the partnership, Vaishali Verma, chief executive officer, Initiative India, said, "We welcome Sensodent into the Initiative family. We look forward to a strong partnership focused on driving brand success and creating meaningful work."
&w=3840&q=100)
Business Standard
23-05-2025
- Business
- Business Standard
What drove Indoco Remedies share price 6% higher today? Top details inside
Indoco Remedies share price: Pharmaceutical company Indoco Remedies shares rose as much as 6.38 per cent to hit an intraday high of Rs 258.20 per share on Friday, May 23, 2025. At 12:10 PM, Indoco Remedies share price was trading 1.77 per cent higher at Rs 247. In comparison, BSE Sensex was trading 0.90 per cent higher at 81,678.93 level. Why did Indoco Remedies share price rise? Indoco Remedies share price rose after the company announced that it has secured final approval of Allopurinol Tablets USP, 200 mg through Company's Abbreviated New Drug Application (ANDA) for Allopurinol Tablets USP to market a generic equivalent to the reference listed drug (RLD), Zyloprim 200 mg of Casper Pharma LLC from USFDA.' Allopurinol is used to prevent or lower high uric acid levels in the blood. It is also used to prevent or lower excess uric acid levels caused by cancer medicines or in patients with kidney stones. Aditi Panandikar, managing director of Indoco Remedies, said, 'Besides reflecting the capability of Indoco Remedies to deliver products of high-quality standards, this development also provides impetus to our growth aspirations in an important market such as the US.' The product will be manufactured by Indoco Remedies Limited at their manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa – 403722 in India, the company revealed. About Indoco Remedies Indoco Remedies is a fully integrated, research-driven pharmaceutical company with a robust global footprint. With a turnover of approximately $180 million, the company is supported by a talented workforce of over 6,000 employees, including more than 400 scientists and an extensive field force. These professionals form the backbone of Indoco's operations, driving innovation and ensuring the delivery of high-quality pharmaceutical products. The company operates 11 state-of-the-art manufacturing facilities—seven dedicated to finished dosage forms (FDFs) and four for active pharmaceutical ingredients (APIs)—along with a cutting-edge R&D centre and a Contract Research Organization (CRO) facility. These facilities are approved by major global regulatory agencies, including the USFDA and UKMHRA. Indoco serves both domestic and international markets, generating over 106 million prescriptions annually through a network of more than 2,40,000 doctors across various specialties. Domestically, it operates through 10 marketing divisions and offers a strong brand portfolio spanning multiple therapeutic areas such as gastroenterology, respiratory care, anti-infectives, ophthalmology, nutrition, cardiology, diabetology, pain management, and gynecology. Some of Indoco's flagship brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, and Glychek. Globally, Indoco partners with leading generic pharmaceutical companies, further strengthening its presence in international markets.
Business Upturn
23-05-2025
- Business
- Business Upturn
Indoco Remedies receives USFDA approval for Generic Allopurinol Tablets USP 200 mg
By Aman Shukla Published on May 23, 2025, 11:20 IST Indoco Remedies Limited has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Allopurinol Tablets USP 200 mg. The approved product is a generic version of Zyloprim® 200 mg, originally marketed by Casper Pharma LLC. Allopurinol is commonly prescribed to manage high levels of uric acid in the blood, a condition known as hyperuricemia. It is also used to control uric acid levels in patients undergoing cancer treatment or those with kidney stones, where elevated uric acid can cause further complications. The approved product will be manufactured at Indoco Remedies' production facility located at L-14, Verna Industrial Area, Verna, Goa – 403722, India. Aditi Panandikar, Managing Director, commented, 'Besides reflecting the capability of Indoco Remedies to deliver products of high-quality standards, this development also provides impetus to our growth aspirations in an important market such as the US.' This approval allows Indoco Remedies to market Allopurinol Tablets USP 200 mg in the U.S. market, providing a therapeutic alternative for patients and contributing to the availability of cost-effective generic medications. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Time of India
14-05-2025
- Business
- Time of India
FCB Ulka wins creative mandate for Sensodent Group
HighlightsFCB Ulka has been appointed as the creative agency on record for Sensodent Group, a specialized oral care brand developed by Indoco Remedies. Indoco Remedies' managing director, Aditi Panandikar, expressed excitement about collaborating with FCB Ulka to elevate the Sensodent brand in the oral sensitivity segment. Kulvinder Ahluwalia, CEO of FCB Ulka, highlighted the brand's potential for growth through culturally resonant storytelling and integrated communication strategies. FCB Ulka (part of FCB India) has been appointed as the creative agency on record for Sensodent Group , a specialised oral care brand developed by Indoco Remedies , a Mumbai-based pharmaceutical company with a strong presence in India and across the globe. As the brand looks further to strengthen its footprint in the oral sensitivity segment , FCB Ulka will lead Sensodent's strategic and creative responsibilities. The account was won following a multi-agency pitch . Commenting on this development, Aditi Panandikar, managing director, Indoco Remedies said, 'Sensodent is our first brand to be placed directly in the hands of consumers and over the past 24 months, we have seen it evolve to the next orbit. We are excited to collaborate with FCB Ulka and look forward to them taking our brand to the next level.' Speaking on the win, Kulvinder Ahluwalia, chief executive officer, FCB Ulka, said, 'Sensodent is a high-efficacy brand with strong credentials in a niche but growing category. We are thrilled to partner with Indoco Remedies to unlock new growth opportunities for the brand through culturally resonant storytelling and integrated communication.'
